에 대한 최신 뉴스 Novo Nordisk (NYSE:NVO) 주식

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

ETFs

$BTC

ACHR

AMGN

SPDR Dow Jones Industrial Average ETF Trust

Market Vectors ETF Trust Market Vectors Gold Miners

LCID

NVDA

PARA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

VKTX

Select Sector SPDR-Consumer Discretionary

S&amp;P 500과 나스닥 100 지수는 2020년 5월 이후 최악의 위축을 겪은 6월 서비스 부문 활동이 예상보다 크게 낮아지자 투자자들이 금리 인하에 대한 기대를 높이면서 목요일 사상 최고치를 경신했다.

연준 회의록을 앞두고 금리 인하 낙관론에 S&amp;P 500, 나스닥 100이 최고치 기록: 금, 채권 랠리

News

Markets

RIVN

화요일 미국 증시는 엇갈린 결과를 보였다. 다우존스 산업평균지수는 0.8% 가까이 하락한 39,112.16으로 마감했다. S&amp;P 500 지수는 약 0.4% 상승한 5,469.30으로 정기 거래를 마감했고, 나스닥 지수는 약 1.3% 상승한 17,717.65에 마감했다. 이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 주요 종목들이다:

화요일 주목받은 주식 5종목: 리비안, 루시드, 마이크론, 노보 노디스크, 테슬라

Health Care

Global

노보 노디스크 A/S(NYSE:NVO)는 체중 감량 약물에 대한 증가하는 수요를 충족하기 위해 미국 제조 사업 확장에 41억 달러를 투자할 예정이다. 무슨 일이 (What Happened): 이 덴마크 제약 회사는 노스캐롤라이나주 롤리(Raleigh) 근처에 140만 평방피트 규모의 새로운 제조 공장을 건설하여 규모를 두 배로 늘릴 계획이라고 보도자료에서 밝혔다. 이 추가 용량은 2027년부터 2029년 사이에 가동될 것으로 예상된다.

위고비와 오젬픽 제조업체인 노보 노디스크가 미국 제조에 41억 달러를 투자 예정

Novo Nordisk A/S

Novo Resources Corp Warrants (27/08/2023)

Novo Integrated Sciences, Inc. - Common Stock

Novo Integrated Sciences Inc

WIIM

Shares of Lilly and Novo Nordisk are trading higher following a study showing patients taking GLP-1 treatments have a reduced risk of developing obesity-related cancers.

In a study published in JAMA Network, patients with type 2 diabetes taking GLP-1 treatments have a reduced risk of developing ten types of obesity-related cancers compared to those on insulin <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39621431/using-obesity-drugs-potential-vision-loss-disorder-linked-to-novo-nordisks-ozempic-and-wegovy-stu" rel="noreferrer noopener">and other diabetes medications</a>.
GLP-1 treatments, including Novo Nordisk&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide (Wegvoy and Ozempic) and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide (Mounjaro and Zepbound), have gained tremendous popularity.
The <a target="_blank" href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820833" rel="noreferrer noopener">research</a> examined the medical records of 1.6 million diabetes patients with no prior history of thirteen types of obesity-related cancers,&nbsp;including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancer, as well as meningioma and multiple myeloma.
The study did not specify the GLP-1 medications used and analyzed data from patients prescribed GLP-1RAs, insulins, or metformin between March 2005 and November 2018.
Researchers found that patients using GLP-1 treatments had a significant reduction in the risk of ten cancers.
The authors noted this as &#8220;preliminary evidence of the potential benefit&#8221; of GLP-1 drugs in cancer prevention for high-risk populations and supported further preclinical and clinical studies to prevent certain obesity-associated cancers.
Novo Nordisk&#8217;s kidney outcomes trial achieved its primary endpoint by demonstrating a statistically significant and superior&nbsp;reduction in kidney disease progression and cardiovascular and kidney death of 24%&nbsp;for people treated with semaglutide 1.0 mg <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37478859/novo-nordisk-says-famed-diabetes-medicine-ozempic-reduces-risk-of-kidney-disease-progression-data" rel="noreferrer noopener">compared to placebo</a>.
In March, the FDA approved Wegovy to reduce the risk of stroke and heart attack in overweight or obese <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37567088/novo-nordisks-game-changer-fda-approves-weight-loss-sensation-wegovy-for-heart-health-potential-i" rel="noreferrer noopener">adults without diabetes</a>.
Eli Lilly&#8217;s detailed results from the SURMOUNT-OSA phase 3 trials evaluating tirzepatide for obstructive sleep apnea achieved all primary and key secondary endpoints for both the efficacy&nbsp;and treatment-regimen&nbsp;estimands and demonstrated a mean reduction of up to 62.8% on <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39454632/eli-lillys-zepbound-for-weight-loss-shows-disease-resolution-in-obese-sleep-apnea-patients-lays-f" rel="noreferrer noopener">the apnea-hypopnea index</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39228957/etfs-bet-high-on-weight-loss-drugs-but-industry-observers-question-long-term-potent" target="_blank" rel="noreferrer noopener">ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential</a>.</li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Biotech

Media

General

GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), the maker of the popular obesity drug Ozempic, has been reprimanded by the U.K.&#8217;s Prescription Medicines Code of Practice Authority (PMCPA) for failing to disclose fees and expenses paid to individuals and organizations in Britain of approximately 7.8 million pounds (around $10 million) between 2020 and 2022.
On Friday, the U.K. industry body PMCPA <a target="_blank" href="https://www.pmcpa.org.uk/about-us/media/news/novartis-pfizer-otsuka-and-novo-nordisk-named-in-advertisements-for-breaches-of-the-abpi-code/" rel="noreferrer noopener">announced</a> that the reprimand followed a voluntary submission by Novo Nordisk regarding these payments.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39600377/joe-biden-suggests-novo-nordisk-eli-lilly-to-lower-prices-for-its-popular-obesity-drugs" rel="noreferrer noopener">Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs</a>.
The PMCPA stated that the payments involved over 150 bodies, including fees and expenses to health professionals, donations, grants, sponsorships, and other payments to healthcare organizations.
Reuters report added that Novo Nordisk explained that these payments were for legitimate activities but were incorrectly categorized in their finance systems due to human error.
The PMCPA also reported breaches of the Association of the British Pharmaceutical Industry&#8217;s (ABPI) code of practice by Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
The agency noted that the breaches discredited and reduced confidence in the pharmaceutical industry.
In March 2023, Novo Nordisk was suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to serious ABPI Code of Practice breaches.
ABPI&#8217;s statement linked to a&nbsp;complaint alleging that Novo Nordisk sponsored courses on weight management on LinkedIn for health professionals without <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31381919/novo-nordisk-suspended-from-uk-trade-association-for-practice-breaches" rel="noreferrer noopener">clarifying the company&#8217;s involvement</a>.
Price Action: NVO shares are
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39621431/using-obesity-drugs-potential-vision-loss-disorder-linked-to-novo-nordisks-ozempic-and-wegovy-stu" target="_blank" rel="noreferrer noopener">Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk&#8217;s Ozempic And Wegovy, Study Finds</a>.</li>
</ul>
Photo via Shutterstock

Government

Regulations

Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures

<a href="https://news.bloomberglaw.com/health-law-and-business/ozempic-may-lower-risk-of-obesity-related-cancers-study-finds" title="https://news.bloomberglaw.com/health-law-and-business/ozempic-may-lower-risk-of-obesity-related-cancers-study-finds">https://news.bloomberglaw.com/health-law-and-business/ozempic-may-lower-risk-of-obesity-related-cancers-study-finds</a>

Hims & Hers Health, Inc. Class A Common Stock

HIMS

'Ozempic May Lower Risk of Obesity-Related Cancers, Study Finds' - Bloomberg Law

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 10 years by 9.02% on an annualized basis producing an average annual return of 19.86%. Currently, Novo Nordisk has a market capitalization of $617.27 billion. 
Buying $100 In NVO: If an investor had bought $100 of NVO stock 10 years ago, it would be worth $611.09 today based on a price of $138.60 for NVO at the time of writing.
<h3>Novo Nordisk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720105232_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today

The S&amp;P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June&#8217;s sharply lower-than-expected services sector activity, which experienced its worst <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39618958/us-services-sector-activity-experiences-largest-contraction-in-over-4-years-gold-ra">contraction since May 2020. </a>
Market-implied odds of a Fed rate cut in September rose from 65% to 72%, according to CME Group&#8217;s FedWatch tool, with traders pricing in more than 50 basis points of rate cuts by year end, implying two fully priced rate reductions by the Fed. 
Risk sentiment was particularly strong ahead of the Federal Open Market Committee (FOMC) Minutes, slated to be released at 2:00 p.m. ET. 
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and the chip making industry, as tracked by the iShares Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NYSE">SOXX</a>), rebounded, up 3.7% and 1.9%, respectively.
Strong gains also stemmed from gold miners, with the VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>) up 4.2%, eyeing one of the best-performing sessions year to date, driven by rising metal prices. 
Expectations of lower interest rates fueled gold prices up by 1.4%, silver up by 3.5%, and copper up by 2.6%. 
Treasury yields weakened sharply, with both the 10-year and 30-year yields down 7 basis points. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) rose 1.1%, rallying the most since June 13. 
However, the crypto market faltered, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) down 2.7% to $60,450.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,168.73</td>
<td>0.8%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,531.06</td>
<td>0.4%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>202.16</td>
<td>0.1 %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,273.72</td>
<td>-0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:28 p.m. ET</figcaption></figure>
According to&nbsp;<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent070324&amp;t=be2bearmibe3na1">Benzinga Pro&nbsp;data:</a>
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;was 0.3% higher to $550.85.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;was 0.2% lower to $392.45.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust&nbsp;(ARCA:&nbsp;<a href="https://www.benzinga.com/quote/qqq" target="_blank" rel="noreferrer noopener"></a><a href="https://www.benzinga.com/quote/qqq" target="_blank" rel="noreferrer noopener"></a>QQQ) was 0.8% higher to $490.70.</li>
<li>Sector-wise, the&nbsp;Technology Discretionary&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)&nbsp;outperformed, up by 1.3%, while the&nbsp;Health Care Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, falling 1%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
<ul>
<li>Weight-loss giant Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) tumbled 1.9% and 4% respectively, after a study conducted by the Massachusetts Eye and Ear showed that Ozempic and Wegovy are linked to higher risk of blinding eye conditions. Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Viking Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) also fell 1.9% and 2.2%, respectively.</li>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares continued their upward momentum from Tuesday, rallying 5.5% after the electric-vehicle maker&#8217;s quarterly deliveries came in better than expected.</li>
<li>Other EV-related stocks also rallied, with Lucid Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) up 8%, Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) up 15%. </li>
<li>Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) surged over 7% following rumors from the Wall Street Journal that Skydance is once again interested in the deal to buy Paramount&#8217;s controlling company, National Amusements.</li>
<li>Constellation Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) fell 4.4%, marking the worst session since October 2023, amid lower-than-expected revenue last quarter. </li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39620397/june-jobs-report-preview-cooling-labor-market-trends-may-further-bolster-rate-cut-h">June Jobs Report Preview: Cooling Labor Market Trends May Further Bolster Rate Cut Hopes</a></li>
</ul>

S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?

A new observational study has identified a potential link between Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) GLP-1 drugs, Ozempic and Wegovy (semaglutide), and a serious eye condition known as nonarteritic anterior ischemic optic neuropathy (NAION), which can <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39429336/nestle-carefully-targets-weight-loss-drug-users-with-new-food-line" rel="noreferrer noopener">lead to vision loss</a>.
NAION refers to a loss of blood flow to the optic nerve (the cable that connects the eye to the brain). This condition typically causes sudden vision loss in one eye without any pain.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39600377/joe-biden-suggests-novo-nordisk-eli-lilly-to-lower-prices-for-its-popular-obesity-drugs" rel="noreferrer noopener">Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs</a>.
The study <a target="_blank" href="https://www.massgeneralbrigham.org/en/about/newsroom/press-releases/popular-prescription-weight-loss-drugs-linked-to-uncommon-blinding-condition" rel="noreferrer noopener">revealed</a> that individuals with diabetes who received and filled a semaglutide prescription were over four times more likely to be diagnosed with NAION.
Additionally, those who were prescribed semaglutide and were overweight or obese had more than seven times the risk of receiving this diagnosis.
The <a target="_blank" href="https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2820255" rel="noreferrer noopener">study</a> reviewed 710 patients with type 2 diabetes, finding that 17 cases of NAION occurred in those prescribed semaglutide, equivalent to a cumulative rate of 8.9% over three years.
Comparatively, six cases were found among patients using non-GLP-1 diabetes drugs, yielding a cumulative rate of 1.8%. Statistical analysis estimated that semaglutide users had a 4.28 times greater risk of developing NAION.
In a separate cohort of 979 overweight or obese patients, 20 cases of NAION were identified in those prescribed semaglutide, resulting in a cumulative rate of 6.7%. Only three cases were found in patients using non-GLP-1 obesity drugs, with a cumulative rate of 0.8%.
This indicated a 7.64 times greater risk for semaglutide users.
Several study limitations were noted. Mass Eye and Ear treats a disproportionately high number of individuals with rare eye diseases, the study population is predominantly white, and there were relatively few NAION cases over the six years, making the statistics volatile.
Additionally, the researchers couldn&#8217;t confirm whether patients consistently took their medication or if they started and then stopped semaglutide, which could have affected their risk.
The study does not establish causality, and the researchers are uncertain about the reasons behind the observed association or the differences between diabetic and overweight groups.
Price Action: NVO shares are down 3.85% at $137.48 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/06/39509637/novo-nordisk-halts-late-stage-study-of-experimental-hypertension-drug-takes-over-800m-impairment-" target="_blank" rel="noreferrer noopener">Novo Nordisk Halts Late-Stage Study Of Experimental Hypertension Drug, Takes Over $800M Impairment Charge</a>.</li>
</ul>
Image via Shutterstock

Movers

Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds

Novo Nordisk and Lilly shares are trading lower amid circulation of a report suggesting a link between Ozempic and higher risk of a serious eye condition.

<a href="https://www.statnews.com/2024/07/03/ozempic-wegovy-naion-vision-loss-study/">https://www.statnews.com/2024/07/03/ozempic-wegovy-naion-vision-loss-study/</a>
A new observational study on Wednesday reported for the first time a potential link between Novo Nordisk's GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision loss.
After hearing anecdotes of patients on the diabetes and obesity drugs experiencing nonarteritic anterior ischemic optic neuropathy, or NAION, researchers at Massachusetts Eye and Ear analyzed data from a registry of patients at their institution to see if there was a broad trend.
Among 710 patients with type 2 diabetes, there were 17 cases of NAION in patients prescribed semaglutide (the scientific name of both drugs). This translated to a cumulative rate of 8.9% over three years. That compares with six cases in patients prescribed non-GLP-1 diabetes drugs, calculated as a cumulative rate of 1.8%. Through statistical analyses, the researchers estimate that there was a 4.28 times greater risk of developing the condition in patients prescribed semaglutide.
Studying 979 patients who were overweight or obese, researchers found 20 cases of NAION in people prescribed semaglutide, calculated as a cumulative rate of 6.7%. In comparison, there were three cases in people prescribed non-GLP-1 obesity drugs, calculated as a cumulative rate of 0.8%. The researchers estimate that there was a 7.64 times greater risk of developing the condition in patients prescribed semaglutide.
 In both the diabetes and obesity cohorts that got semaglutide, the researchers found that NAION cases occurred most frequently in the first year after the medications were prescribed.
NAION, sometimes referred to as an "eye stroke," occurs from a lack of sufficient blood flow to the optic nerve. It typically causes sudden vision loss and, in severe cases, can lead to blindness. There are currently no proven treatments for the condition.
NAION was not reported as an adverse event in trials studying semaglutide. As drugs go on the market and many more people take them, it's common for doctors to find new rare side effects that weren't seen in the controlled studies.
The authors stress, though, that this observational study does not show that the drugs cause higher rates of NAION — just that there is a potential association. The study also focused only at semaglutide, and the findings can't be immediately generalized to other GLP-1 drugs. The researchers still believed it's important to report the findings to spur further analysis and to make doctors and patients aware.
"This study shows an association that we didn't know about before, and what it should do is give people added information to make a good, well-informed decision about them taking the medicine," said Joseph Rizzo, senior author on the study and a neuro-ophthalmologist at Mass Eye and Ear. "It doesn't mean they shouldn't take it. People are going to have a different sense of risk about whether they want to take it or not."
In a statement, Novo said that "patient safety is a top priority" and that it takes "all reports about adverse events from use of our medicines very seriously." NAION is not an adverse event listed on the approved labels, and the new study was not designed to establish a causal relationship, the company said.
"Semaglutide has been studied in large real world evidence studies and robust clinical development programs," Novo added. "The totality of data provides reassurance of the safety profile of semaglutide."
There were several limitations to the study. While the researchers manually reviewed each case of NAION, they did not report how severe the cases of NAION were and how much vision people lost. Rizzo said a much larger study would be needed to power that kind of analysis.
Additionally, while the researchers confirmed that the prescribed doses of semaglutide were dispensed, they could not track whether patients actually took the medications and adhered to them.
There may also have been confounding variables. Type 2 diabetes and high blood pressure are risk factors for NAION. It's possible that patients with more severe diabetes or high blood pressure were more likely to be prescribed semaglutide, as it's a highly effective drug, and that may have played into the higher rates of NAION in those cohorts.
Susan Mollan, a consultant neuro-opthamologist at University Hospitals Birmingham in the U.K., who wasn't involved in the study, said the findings are somewhat surprising since GLP-1 drugs have been found in early studies to reduce inflammation and protect nerves.
She said it's important in future research to determine whether higher rates of NAION may be linked to direct effects of the drugs or to the biological changes in people taking the drugs.
For example, researchers have seen in trials that people taking semaglutide had higher rates of a different eye condition called diabetic retinopathy. Although study of the condition is ongoing, researchers believe it may be caused by a rapid decrease in people's blood sugar levels. Mollan said it's possible that the normalization of people's metabolic systems, rather than the drugs itself, may help explain the NAION cases.
Overall, though, Mollan said the new study is "a very important paper."
"When you first get these kinds of signals, we need to apply caution to what we're hearing, but also we need to protect our patients," she added. "I'd want eye doctors, endocrinology doctors, and physicians that prescribe the drug to be aware that this has been reported and await further data of a population study to help us talk about the risk."

Novo Nordisk Shares See Further Drop; 'Study Links Ozempic To Higher Risk Of Eye Condition That Can Cause Vision Loss' - STAT News

<a href="https://nypost.com/2024/07/03/lifestyle/potential-link-between-ozempic-wegovy-and-serious-eye-condition-study/">https://nypost.com/2024/07/03/lifestyle/potential-link-between-ozempic-wegovy-and-serious-eye-condition-study/</a>
Researchers say they have uncovered a link between semaglutide — the active ingredient in <a href="https://nypost.com/2024/06/24/lifestyle/ozempic-user-reveals-psychological-downside-after-losing-42-lbs/">Ozempic</a> and <a href="https://nypost.com/2024/03/08/business/weight-loss-drug-wegovy-approved-by-fda-to-cut-heart-attack-stroke-risk/">Wegovy</a> — and sudden&nbsp;vision&nbsp;loss.
The risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) is four times higher for diabetics on semaglutide and seven times higher for people taking the <a href="https://nypost.com/2024/07/02/lifestyle/former-ozempic-user-taking-new-experimental-drug-retatrutide/#:~:text=Kearns%20told%20the%20news%20station,being%20dubbed%20%E2%80%9COzempic%20face.%E2%80%9D">drug to lose weight</a>, according to <a href="https://www.eurekalert.org/news-releases/1050055">a new study </a>from Massachusetts Eye and Ear, a teaching hospital of Harvard Medical School.
A relatively rare condition, NAION is believed to be caused by insufficient blood flow to the optic nerve head. The result is painless but irreversible vision loss in one eye. There are no effective treatments for NAION.
NAION is not fully understood — and neither is the purported relationship between semaglutide and the optic nerve disorder.
"This study is the first, to our knowledge, to report an association between semaglutide and NAION, although the design of our study did not enable query into a causal relationship between the two," the researchers wrote in their findings, published Wednesday in the journal <a href="https://doi.org/10.1001/jamaophthalmol.2024.2296">JAMA Ophthalmology</a>.

'Potential Link Between Ozempic, Wegovy And Serious Eye Condition Revealed In New Study' - New York Post

The President of the United States, Joe Biden, and Sen. Bernie Sanders, the Senate Chairman of the Health, Education, Labor, and Pensions Committee, have long been vocal about the exorbitant prices the pharmaceutical industry charges for prescription drugs in the U.S.
Americans pay the highest prices globally for essential medications, with 1 in 4 unable to afford the prescriptions their doctors recommend, the USA Today <a target="_blank" href="https://www.usatoday.com/story/opinion/2024/07/02/biden-sanders-prescription-drug-cost-ozempic-wegovy/74232827007/" rel="noreferrer noopener">highlighted</a>.
The argument that high domestic prices subsidize fair prices abroad is unacceptable, Biden said.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/01/36679937/medicare-patients-alert-biden-administration-finalizes-rule-to-streamline-health-insurance-prior-aut" rel="noreferrer noopener">Medicare Patients Alert! Biden Administration Finalizes Rule to Streamline Health Insurance Prior Authorization</a>.
Significant strides have been made recently to address these issues. The Inflation Reduction Act passed without a single Republican vote, has capped insulin <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31394427/three-is-company-sanofi-follows-lilly-novo-nordisk-slashes-insulin-product-price-by-78" rel="noreferrer noopener">costs at $35 per month</a> for seniors with diabetes.
Starting in January, no senior will pay more than $2,000 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36641146/financial-relief-for-medicare-patients-part-d-overhaul-caps-out-of-pocket-drug-cost-limits" rel="noreferrer noopener">annually for prescription drugs</a>, the report added.
Additionally, Medicare will now negotiate with pharmaceutical companies to lower the prices of the most expensive medications.
These policies have widespread public support, with more than 60% of Republicans in agreement. Collaborative efforts have also led to reducing inhaler costs from $645 to $35 for millions of Americans with asthma and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37866510/senator-bernie-sanders-applauds-gsks-move-to-cap-inhaler-costs-at-35-per-month" rel="noreferrer noopener">chronic obstructive pulmonary disease</a>.
The proposed legislation aims to expand the number of drugs eligible for price negotiation to at least 50 per year.
The U.S. government must continue to challenge Big Pharma, and drug companies must cease overcharging Americans, Biden said.
For example, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) charges excessively for its blockbuster obesity drugs, Ozempic and Wegovy, despite manufacturing costs being <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37989566/how-much-does-it-cost-to-make-novo-nordisks-ozempic-shockingly-low-against-1-000-price-tag-study-" rel="noreferrer noopener">less than $5 per month</a>.
Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) also charges over $1,000 per month for Mounjaro, a drug for diabetes and weight loss.
The disparity in drug prices between the U.S. and other countries like Canada, Germany, and Denmark is stark.
A Yale University study found that Ozempic and Wegovy could be profitably manufactured for significantly less than their current prices.
The potential costs of widespread use of weight loss drugs like Wegovy could exceed what Americans currently spend on all prescription drugs.
Pharmaceutical companies must balance profit with social responsibility, said Biden.
Last year, the top 10 pharmaceutical companies made over $110 billion in profits. In 2023, Novo Nordisk&#8217;s profits exceeded $12 billion, partly due to high prices for medications like Ozempic.
Pharmaceutical companies argue that opaque discounting mechanisms and high prices are necessary for innovation. However, fair prices for consumers are balanced with rewarding innovation.
If companies like Novo Nordisk do not reduce drug prices, legislative measures will be taken to enforce price reductions, Biden said.
Ensuring affordable prescription drugs for all Americans is a moral and fiscal responsibility.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/05/39042551/novo-nordisk-faces-scrutiny-over-high-prices-of-ozempic-and-wegovy-blames-us-health-system" target="_blank" rel="noreferrer noopener">Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System</a>.</li>
</ul>
Price Action: LLY shares are down 1.79% at $897.88, and NVO stock is down 2.04% at $142.47 at the last check on Tuesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by Tobias Arhelger via Shutterstock

Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs

Market Summary

Benzinga Market Summary: Powell Speaks At ECB, Tesla Surges On Delivery Figures, Biden Admin Launches US Chip Workforce Program, Novo Nordisk Falls After Biden Urges Ozempic Price Cut

U.S. FDA Sends Warning Letter To Ozempen.com; FDA Observed That www.ozempen.com Introduces Into Interstate Commerce Unapproved And Misbranded Semaglutide Drug Products; Requests Cease Offering Any Unapproved And Misbranded Drugs For Sale To U.S. Consumers

<a href="https://www.usatoday.com/story/opinion/2024/07/02/biden-sanders-prescription-drug-cost-ozempic-wegovy/74232827007/" title="https://www.usatoday.com/story/opinion/2024/07/02/biden-sanders-prescription-drug-cost-ozempic-wegovy/74232827007/">https://www.usatoday.com/story/opinion/2024/07/02/biden-sanders-prescription-drug-cost-ozempic-wegovy/74232827007/</a>

'Biden Urges Novo Nordisk To Cut Ozempic And Wegovy Prices' - USA Today Op-Ed

Novo Nordisk shares are trading lower after Biden reportedly said the company must cut Ozempic and Wegovy prices.

Analysts' ratings for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Novo Nordisk and provided 12-month price targets. The average target is $160.75, accompanied by a high estimate of $163.00 and a low estimate of $160.00. This upward trend is apparent, with the current average reflecting a 3.93% increase from the previous average price target of $154.67.
<img src="https://www.benzinga.com/files/images/story/2024/1719849677_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Novo Nordisk by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>John Eade</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$163.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Novo Nordisk. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Novo Nordisk compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Novo Nordisk's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Novo Nordisk's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NVO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Novo Nordisk analyst ratings.</a>
<h2>About Novo Nordisk</h2>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
<h3>Novo Nordisk: Financial Performance Dissected</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Novo Nordisk's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 22.45%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Novo Nordisk's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.88% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Novo Nordisk's ROE excels beyond industry benchmarks, reaching 24.73%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Novo Nordisk's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.28% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Novo Nordisk's debt-to-equity ratio is below the industry average at 0.27, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Beyond The Numbers: 8 Analysts Discuss Novo Nordisk Stock

Cantor Fitzgerald analyst Louise Chen reiterates Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) with a Overweight and maintains $160 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for Novo Nordisk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 41% bearish. Among these notable options, 3 are puts, totaling $153,000, and 14 are calls, amounting to $1,309,591.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $155.0 for Novo Nordisk, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale activity within a strike price range from $120.0 to $155.0 in the last 30 days. 
<h3>Novo Nordisk Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1719603088_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$6.05</td>
<td>$5.95</td>
<td>$6.0</td>
<td>$150.00</td>
<td>$328.8K</td>
<td>3.6K</td>
<td style="text-align: right;">491</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$11.65</td>
<td>$11.55</td>
<td>$11.65</td>
<td>$150.00</td>
<td>$143.2K</td>
<td>1.1K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$17.3</td>
<td>$17.05</td>
<td>$17.3</td>
<td>$145.00</td>
<td>$133.4K</td>
<td>535</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$25.0</td>
<td>$23.95</td>
<td>$24.41</td>
<td>$150.00</td>
<td>$122.1K</td>
<td>1.7K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$4.85</td>
<td>$4.8</td>
<td>$4.84</td>
<td>$155.00</td>
<td>$121.2K</td>
<td>1.2K</td>
<td style="text-align: right;">2</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Following our analysis of the options activities associated with Novo Nordisk, we pivot to a closer look at the company's own performance.
<h3>Current Position of Novo Nordisk</h3>
<ul>
<li>Trading volume stands at 1,671,110, with NVO's price down by -0.69%, positioned at $143.49.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 41 days.</li>
</ul>
<h3>What Analysts Are Saying About Novo Nordisk</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $160.75.
<ul>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160. </li>
<li>Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Novo Nordisk, targeting a price of $163. </li>
<li>An analyst from Argus Research persists with their Buy rating on Novo Nordisk, maintaining a target price of $160. </li>
<li>Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $160.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novo Nordisk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Novo Nordisk Options Trading: A Deep Dive into Market Sentiment

Novo Nordisk&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvo#NYSE">NVO</a>) lost 2.2% on Jun 26 after the company announced the failure of a late-stage study evaluating ocedurenone&nbsp;to treat patients with uncontrolled hypertension and advanced chronic kidney disease (CKD). Consequently, the company said that it will recognize an impairment loss of around DKK 5.7 billion related to the intangible assets in the second quarter of 2024.
Such recognition is expected to negatively impact operating profit growth by around 6 percentage points at the constant exchange rate (CER) in 2024. This adjustment revises the previously stated operating profit outlook of 22% to 30% growth at CER, as communicated in their financial report for the first quarter of 2024.
Novo Nordisk is slated to announce its financial results for the first six months of 2024 and update its financial outlook for 2024 on Aug 7, 2024.
Based on interim analysis, an independent data monitoring determined that the study did not meet its primary endpoint of reducing systolic blood pressure from baseline. This conclusion triggered Novo Nordisk&#39;s decision to halt the CLARION-CKD study.
Year to date, shares of NVO have jumped 38.9% compared with the industry&#39;s 23.1% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/42/69713.jpg?v=1773182169" style="height:350px; width:600px" /> 
Image Source: Zacks Investment Research
The investigational candidate, ocedurenone, is a novel third-generation non-steroidal mineralocorticoid receptor antagonist known for its distinct pharmacokinetic profile, featuring a prolonged half-life and strong affinity for the mineralocorticoid receptor.
Novo Nordisk acquired ocedurenone from KBP Biosciences in 2023. The phase III CLARION-CKD study, conducted by KBP Biosciences, aimed to assess ocedurenone&#39;s efficacy inmore than 600 enrolled patients with uncontrolled hypertension and advanced CKD, a condition for which effective treatments are critically needed. The study included a prespecified interim analysis after 12 weeks of treatment for all patients.
The decision to stop the trial underscores the challenges in developing effective therapies for complex conditions like advanced CKD and uncontrolled hypertension. The failure of ocedurenone brought into question the viability of the KBP Biosciences deal.
<h3>Zacks Rank and Stocks to Consider</h3>
Novo Nordisk currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the drug/biotech industry are ALX Oncology Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alxo#NASDAQ">ALXO</a>), Annovis Bio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anvs#NYSE">ANVS</a>) and Compugen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgen#NASDAQ">CGEN</a>), each carrying a Zacks Rank #2 (Buy) at present.
In the past 30 days, the Zacks Consensus Estimate for ALX Oncology&#39;s 2024 loss per share has remained constant at $2.89. During the same period, the consensus estimate for 2025 loss per share has remained constant at $2.73. Year to date, shares of ALXO have plunged 60.5%.
ALX Oncology beat estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 8.83%.
In the past 30 days, the Zacks Consensus Estimate for Annovis&#39; 2024 loss per share has remained constant at $2.46. During the same period, the consensus estimate for 2025 loss per share has remained constant at $1.95. Year to date, shares of ANVS have plunged 69.4%.
ANVS beat estimates in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%.
In the past 30 days, the Zacks Consensus Estimate for Compugen&#39;s 2024 earnings per share has remained constant at 5 cents. The consensus estimate for 2025 loss per share is currently pegged at 11 cents. Year to date, shares of CGEN have lost 11.6%.
CGEN&#39;s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 5.79%.
<a href="https://www.zacks.com/stock/news/2294455/novo-nordisk-s-nvo-hypertension-drug-study-fails-to-meet-goal?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2294455">To read this article on Zacks.com click here.</a>

Earnings

Penny Stocks

Small Cap

ALXO

ANVS

CGEN

Novo Nordisk's Hypertension Drug Study Fails to Meet Goal

On Thursday, 2seventy Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy&#8217;s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune <a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/b39512087/2seventy-bio-announces-sale-of-hemophilia-a-candidate-and-megatal-in-vivo-gene-editing-technology-" rel="noreferrer noopener">cells for autoimmune disease</a>.
The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology.
Related: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38114915/fda-approves-bristol-myers2seventy-bios-abecma-for-earlier-use-in-pretreated-blood-cancer-patient" rel="noreferrer noopener">FDA Approves Bristol-Myers/2seventy Bio&#8217;s Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer</a>.
The program is based on the original research agreement, established in 2019, which focused on a gene editing therapy for Hemophilia A.
2seventy bio will focus exclusively on the commercialization and continued development of&nbsp;Abecma&nbsp;(idecabtagene vicleucel), its BCMA-targeted CAR T cell therapy for multiple myeloma, in collaboration with Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>).
&#8220;We are pleased to announce the completion of this APA with Novo Nordisk as we believe it will provide the appropriate resources for both the team and the science behind this important program,&#8221; said Chip Baird, CEO, 2seventy bio.
Under the terms of the agreement, 2seventy will potentially receive payments of up to $40 million.
2seventy will transfer the Hemophilia A program to Novo Nordisk, and the existing collaboration agreement will be terminated.
Additionally, the divestiture will include the transfer of 2seventy Bio&#8217;s megaTAL technology and a license to the underlying intellectual property.
Read Next: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38334543/fda-mandates-boxed-warning-for-bristol-myers-johnson-johnson-car-t-based-blood-cancer-therapies" rel="noreferrer noopener">FDA Mandates &#8220;Boxed Warning&#8221; For Bristol Myers, Johnson &amp; Johnson CAR-T-Based Blood Cancer Therapies</a>.
Price Action: TSVT shares are up 4.58% at $3.77 at last check Thursday.

TSVT

Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The COVID-19 pandemic emphasized the importance of healthcare companies. Consistent breakthroughs, improved products and relatively consistent growth make these companies fan-favorite picks for investors. The production of new medicines often is the most important catalyst for these companies; the millions of dollars spent in research and development culminate in regulatory approval. If successful, investors can see their portfolios magically jump in size overnight. If not, the slump can be brutal. This double-sidedness is also why some investors are hesitant to jump into this sector.



However, with a compounded annual growth rate (CAGR) of <a href="https://www.verifiedmarketresearch.com/product/healthcare-services-market/">8.27</a>%, the sector as a whole is expected to grow, making it a suitable investment. With rapid innovation, the companies discussed today are likely to outpace the market &mdash; providing you with handsome returns should you invest.



<h2>Abbott Laboratories (ABT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/abt1600-300x169.jpg" alt="Abbott (ABT) sign with lighting behind letters"><div>Source: testing / Shutterstock.com</div></div>Abbott Laboratories (NYSE:<a href="https://investorplace.com/stock-quotes/abt-stock-quote/">ABT</a>) is a global healthcare company engaged in the discovery, development, manufacture and sale of a broad and diversified line of healthcare products. These include diagnostic tests, medical devices, nutritional products and branded generic pharmaceuticals.



ABT stock is currently trading at <a href="https://finance.yahoo.com/quote/ABT/">$103.20</a> and has a market cap of <a href="https://finance.yahoo.com/quote/ABT/">$179.5 billion</a>. The company has positive financials, with profit and operating margins of 14% and 15.4% respectively. The stock has consistently beaten EPS predictions for the past year with an average EPS surprise of 2.43%. Analysts believe that the stock is underpriced right now, and have set a price target of <a href="https://finance.yahoo.com/quote/ABT/">$125.18</a> for the stock, indicating potential upside of 21%.



Another reason investors might want to go for this stock is its dividend. Abbott currently offers a dividend yielding around <a href="https://www.nasdaq.com/market-activity/stocks/abt/dividend-history">2.13%</a>, which is attractive for income-seeking investors. The company has a strong track record of dividend payments. It has increased its dividend for 29 consecutive years, making it a Dividend Aristocrat.



This commitment to returning value to shareholders makes ABT an appealing option for long-term investors looking for both growth and income. With strong financials, a promising price target and a reliable dividend yield, Abbott Laboratories is the best healthcare stock to buy.



<h2>Amgen (AMGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/11/amgn-stock-1-300x169.jpg" alt="the Amgen (AMGN) logo on a building during daylight"><div>Source: Michael Vi / Shutterstock.com</div></div>Amgen (NASDAQ:<a href="https://investorplace.com/stock-quotes/amgn-stock-quote/">AMGN</a>) is a leading biotechnology company that discovers, develops, manufactures and delivers innovative human therapeutics. The company primarily focuses on areas of high unmet medical needs and leverages its expertise in molecular biology and biochemistry to develop therapies that improve patient outcomes.&nbsp;



AMGN stock has seen positive profit and operating margins of <a href="https://finance.yahoo.com/quote/AMGN/key-statistics/">12.74%</a> and <a href="https://finance.yahoo.com/quote/AMGN/key-statistics/">13.33%</a>. The company has seen steady revenue increases over the past four years, rising by 10.8% from $25.42 billion in 2020 to $28.19 billion in 2023. The company has also consistently beaten EPS predictions over the past year by impressive margins.



Amgen, like Abbott Laboratories, has provided investors with good dividends with a yield of 2.89%. Amgen&rsquo;s entry into the obesity drug market with a <a href="https://clinicaltrials.gov/study/NCT05669599">promising clinical trial</a> for weight loss has driven a stock surge. It pushed shares near all-time highs. Promising financials, great dividends and recent developments make Amgen one of the best <a href="https://investorplace.com/industries/healthcare/">healthcare stocks</a> to buy.



<h2>Eli Lilly (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/03/eli-lilly-lly-stock-sign-1600-300x169.jpg" alt="Eli Lilly (LLY) sign on corporate building with blue sky in background"><div>Source: shutterstock.com/Michael Vi</div></div>Eli Lilly (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>) is among the most widely known pharmaceutical companies. It is particularly famous for its insulin, though it does also have other drugs under its umbrella. A notable one is the weight-loss drug Zepbound, which is a direct competitor to Novo Nordisk&rsquo;s (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>) Ozempic. LLY has a steady stream of products rolling in but certain challenges may limit stock growth potential.



LLY stock has great financials with profit and operating margins of <a href="https://finance.yahoo.com/quote/LLY/key-statistics/">17.08%</a> and 31.20% respectively. The company has seen a year-on-year quarterly revenue growth of 26% with earnings growth of 66.80% in the same period. An operating cash flow of $3.68 billion further solidifies this.



Recently, LLY&rsquo;s <a href="https://www.investors.com/news/technology/eli-lilly-stock-fda-approval-alzheimers-treatment-kisunla/?src=A00220">Alzheimer&rsquo;s drug</a> was approved. This drug is a testament to the regular innovations done by LLY. However, it didn&rsquo;t affect the market too much. There is a lot of <a href="https://finance.yahoo.com/news/novo-lilly-slip-biden-demands-130236373.html">negative news</a> floating around, particularly regarding the Biden administration&rsquo;s plans to lower the prices of key drugs. This is understandably worrisome news for investors, though it hasn&rsquo;t come to fruition yet. Analysts suggest this could be a last-ditch political move.



Investors should focus on the fundamentals of LLY. They are great at the moment and indicate impressive growth potential over the long run. They make it one of the best healthcare stocks to put your money in.



On the date of publication, Achintya Pasricha did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Achintya Pasricha is a self-taught investor who has recently started to publish articles on a freelance basis.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/the-3-best-healthcare-stocks-to-buy-in-july-2024/">The 3 Best Healthcare Stocks to Buy in July 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 3 Best Healthcare Stocks to Buy in July 2024

Deutsche Numis analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK1,100...

Deutsche Numis Remains a Buy on Novo Nordisk (0QIU)

Global Anti-Obesity Market Analysis: Key Trends And Insights

Novo Nordisk: Buy On Dips

Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum

Danish drugmaker Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has been reprimanded (an official statement of disapproval) by UK regulators for not disclosing around £7....

Novo Nordisk (NYSE:NVO) Gets Reprimanded by UK Regulators

Study links GLP-1 drugs, metformin to lower risk of certain cancers

Recently, there was a small study published that suggested there is a link between Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) obesity drug semaglutide and an eye di...

Novo Nordisk's (NYSE:NVO) Ozempic Linked to Lower Risk of Cancer

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Savvy investors are discovering rewarding opportunities in some of the best stocks under $10 a share.



Years ago, I found Advanced Micro Devices (NASDAQ:<a href="https://investorplace.com/stock-quotes/amd-stock-quote/">AMD</a>) at $10 a share and watched it rocket above $200 on the artificial intelligence (AI) boom. Netflix (NASDAQ:<a href="https://investorplace.com/stock-quotes/nflx-stock-quote/">NFLX</a>) briefly traded around $10 before exploding higher, splitting twice. Even Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>) was once well under $10 a share before ramping splitting six times.



And there&rsquo;s plenty more just like these.



Just look at the weight loss drug story, for example. In late 2022, Viking Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vktx-stock-quote/">VKTX</a>) traded at around $5 a share. Now thanks to its drug trial success, it&rsquo;s up to $50.



With more opportunities, investors can uncover AI, machine learning, weight loss treatment stocks, green energy, electric vehicles (EVs), metals and more.&nbsp;You just need to take the time to do the research and spot hot trends before they become explosive.&nbsp;



Let&rsquo;s delve into a few best stocks under $10 a share you may want to jump on today.



<h2>Altimmune (ALT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/drug_stocks1600-300x169.jpg" alt="dollar sign written with pills spilled from a medicine bottle. millionaire maker drug stocks"><div>Source: Shutterstock</div></div>At $6.60,&nbsp;Altimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/alt-stock-quote/">ALT</a>), a clinical-stage biopharmaceutical developing pemvidutide, a GLP-1/glucagon dual receptor agonist for weight loss, is a steal.



It may also have the same fiery potential we&rsquo;ve seen with other weight loss drug stocks.



Most recently, the company released Phase 2 data on its&nbsp;drug candidate pemvidutide, which showed that participants lost a mean of 15.6% of body weight at 48 weeks based on the highest dose tested.



Reportedly, <a href="https://seekingalpha.com/news/4118343-altimmune-jumps-13-phase-2-pemvidutide-results-obesity">the treatment also led to</a> &ldquo;better lean mass preservation compared to other marketed incretin mimetic medications, such as Novo Nordisk&rsquo;s (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>) Wegovy (semaglutide) and Eli Lilly&rsquo;s (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>) Zepbound (tirzepatide).&rdquo;



After all, preservation of lean mass with weight loss is critical, says the company. If a person loses too much lean mass during weight loss, it can lead to severe medical outcomes, such as musculoskeletal issues and bone fractures.



That news alone could be a massive game changer for ALT.&nbsp;



<h2>Arcadium Lithium (ALTM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/05/lithium1600d-300x169.jpg" alt="Graphic of Lithium scientific symbol (Li) in the shape of a big white gear with construction equipment and mountain around it. favorite Lithium stocks"><div>Source: GrAl / Shutterstock.com</div></div>Another one of the best stocks under $10 is Arcadium Lithium (NYSE:<a href="https://investorplace.com/stock-quotes/altm-stock-quote/">ALTM</a>).



First, lithium prices appear to be bottoming out. Next,&nbsp;analysts at&nbsp;Fastmarkets say demand for lithium in the U.S.&nbsp;could <a href="https://www.fastmarkets.com/insights/us-lithium-demand-to-grow-fastmarkets-provide-regional-price-transparency/#:~:text=Fastmarkets%20forecasts%20a%20significant%20growth,for%20the%20US%20and%20Europe.">grow by 487%</a> to 412,000 tons by the time 2030 rolls around. Should that happen, a shortage of supply coupled with explosive demand will lead to another massive spike in lithium. Third, we&rsquo;re just starting to see a pickup in electric vehicle (EV) demand, which will lead to an increase in lithium demand. And that will eventually lead to higher valuations for beaten-down <a href="https://investorplace.com/industries/energy/renewable-energy/battery/lithium/">lithium stocks</a>, like ALTM.



Additionally, analysts at RBC Capital just initiated a buy rating on the stock with a price target of $4, noting that ALTM &ldquo;will increase lithium carbonate equivalent production from 61K tons in 2023 to 142K tons in 2027, a five-year compound annual growth rate of 23%, resulting in earnings tripling over the period,&rdquo; <a href="https://seekingalpha.com/news/4119722-arcadium-lithium-started-at-outperform-at-rbc-driven-by-strong-production-growth">as noted by Seeking Alpha</a>.



<h2>Arcutis Biotherapeutics (ARQT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>The last time I highlighted an opportunity in Arcutis Biotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/arqt-stock-quote/">ARQT</a>), it traded at $2.30 on <a href="https://investorplace.com/2023/11/3-biotech-stocks-with-key-catalysts-coming-in-december/">Nov. 15, 2023</a>. That was just weeks ahead of a favorable Dec. 15 U.S. Food and Drug Administration (FDA) ruling, which we used as our initial catalyst for buying the stock.&nbsp;&nbsp;Today, ARQT is up to $9.92, and it&rsquo;s still a buy.



Recent earnings were equally as impressive.&nbsp;



Its earnings per share loss of 32 cents beat by 41 cents. Meanwhile, revenue of $49.57 million &ndash; <a href="https://seekingalpha.com/pr/19725290-arcutis-announces-first-quarter-2024-financial-results-and-provides-business-update?hasComeFromMpArticle=false&amp;source=section%253Amain_content%257Cbutton%253Abody_link%257Cfirst_level_url%253Anews">up 1,682.4% year-over-year (YOY)</a> &ndash; beat by $34.43 million.&nbsp;Also, the company saw substantial growth with Zoryve (roflumilast) treatment for plaque psoriasis and seborrheic dermatitis. Revenue for that was $21.6 million, an increase of about 676% YOY.



Upcoming on July 7, the company has a <a href="https://investors.arcutis.com/news-releases/news-release-details/fda-accepts-arcutis-supplemental-new-drug-application">U.S. FDA PDUFA date for its Zoryve</a> cream as a potential treatment for atopic dermatitis. So far, all I know is that its supplemental news drug application (sNDA) on Zoryve is supported by three positive Phase 3 results.



<h2>XPeng (XPEV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/dealership-evs-xpeng-xpev-1600-300x169.jpg" alt="Xpeng (XPEV) car dealership at night with white company logo on display above EVs"><div>Source: shutterstock.com/Robert Way</div></div>Another one of the best stocks under $10 is XPeng&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/xpev-stock-quote/">XPEV</a>), which is ticking higher with multiple catalysts.&nbsp;



First, its X2 flying car just took its first flight at the&nbsp;<a href="https://www.techtimes.com/articles/305724/20240616/xpengs-aeroht-x2-flying-car-beijing-airport-maiden-flight.htm">Beijing Daxing International Airport</a>. Second, the&nbsp;company wants to commercialize flying cars by the end of the year.&nbsp;



And third,&nbsp;<a href="https://asia.nikkei.com/Business/China-tech/China-s-Guangzhou-to-invest-1.4bn-in-flying-car-infrastructure#:~:text=HONG%20KONG%20%2D%2D%20Guangzhou%20will,to%20speed%20up%20sluggish%20growth.">China&rsquo;s&nbsp;Guangzhou</a>&nbsp;will invest more than $1.4 billion by 2027 in the &ldquo;low-altitude economy,&rdquo; says&nbsp;Nikkei Asia. We also have to consider that China is providing substantial support to flying car companies.



In addition, XPEV EV growth has been impressive. In June, for example, the company delivered 10,668 Smart EVs, a 24% YOY jump. For the first half of the year, it&rsquo;s delivered 52,028 Smart EVs, a 26% YOY jump. Additionally,&nbsp;analysts at&nbsp;<a href="https://www.moomoo.com/news/post/38577168/daiwa-upgrades-xpeng-xpevus-to-buy-rating-raises-target-price">Daiwa recently upgraded the XPEV stock</a>&nbsp;to a buy rating with a price target of $11.&nbsp;



<h2>SoundHound AI (SOUN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/soun1600-1-300x169.png" alt="In this photo illustration, the SoundHound logo seen displayed on a smartphone. SOUN stock"><div>Source: rafapress / Shutterstock.com</div></div>SoundHound AI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) provides voice control and audio analytics software to automakers, drive-through restaurants and other businesses with phone-based menu systems.



It also counts Nvidia as a major investor with its $3.7 million investment in the company. Even the investment arm of&nbsp;SoftBank&nbsp;(OTCMKTS:<a href="https://investorplace.com/stock-quotes/sftby-stock-quote/">SFTBY</a>) invested $2.3 million in the stock. Those investments are on the small side, but it says a lot that industry giants are jumping into the underappreciated name.



Apple&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/aapl-stock-quote/">AAPL</a>) integrated its technology into hardware devices.&nbsp;Netflix&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nflx-stock-quote/">NFLX</a>),&nbsp;Honda&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/hmc-stock-quote/">HMC</a>),&nbsp;Pandora&nbsp;(OTCMKTS:<a href="https://investorplace.com/stock-quotes/pandy-stock-quote/">PANDY</a>),&nbsp;Square&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/sq-stock-quote/">SQ</a>) and&nbsp;Mastercard&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/ma-stock-quote/">MA</a>) use it. Even restaurants like Jersey Mike&rsquo;s,&nbsp;Chipotle&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/cmg-stock-quote/">CMG</a>), and&nbsp;Papa John&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/pzza-stock-quote/">PZZA</a>) are using the technology.



Plus, according to analysts at Wedbush, the company raised the low-end of its revenue&nbsp;guidance for the full year to $77 million from $65 million.&nbsp;



Also, the firm noted that the raise was indicative that SoundHound is &lsquo;well-positioned&rsquo; to capitalize on the demand for AI chatbots as it partners with various companies, including restaurants,&rdquo;&nbsp;<a href="https://seekingalpha.com/news/4104627-soundhound-ai-jumps-as-wedbush-says-ai-momentum-is-front-and-center">as quoted by Seeking Alpha</a>.



<h2>Trulieve Cannabis (TCNNF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/tcnnf-stock-1600-300x169.jpg" alt="Florida licensed medical marijuana cannabis provider Trulieve"><div>Source: Leigh Trail / Shutterstock.com</div></div>With the election nearing, rescheduling and a key cannabis vote in Florida in November, <a href="https://investorplace.com/industries/healthcare/cannabis/">cannabis stocks</a> like Trulieve Cannabis (OTCMKTS:<a href="https://investorplace.com/stock-quotes/tcnnf-stock-quote/">TCNNF</a>) could race to higher highs. Also, consider that when about 88% of Americans want to see legalization, more states could vote to approve it.



And at some point, we may even see federal approval. In the meantime, when it comes to TCNNF, the key catalyst is the Florida vote. Remember,&nbsp;the Supreme&nbsp;Court&rsquo;s&nbsp;decision to allow the legalization of cannabis to appear on ballots this November holds the key to unlocking a potential tripling of the total cannabis market in Florida to $6 billion in sales,&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38037571/floridas-6b-cannabis-market-anticipates-400-growth-following-court-decision-allowin" target="_blank">as noted by Benzinga.com</a>.



Furthermore, earnings have been strong.&nbsp;Its first-quarter <a href="https://investorplace.com/earning-results/2024/05/tcnnf-stock-earnings-trulieve-cannabis-for-q1-of-2024/">EPS loss of five cents beat by six cents</a>.&nbsp;Revenue of $298 million, up 4.6% YOY, beat by $12.27 million.&nbsp;Also, Trulieve Cannabis generated a free cash flow from operations of $139 million and a free cash flow of $124 million.&nbsp;



<h2>JetBlue (JBLU)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/jblu-stock-3-300x169.jpg" alt="jetblue (JBLU) airplane on a runway"><div>Source: Roman Tiraspolsky / Shutterstock.com</div></div>Weakness in <a href="https://investorplace.com/industries/consumer-discretionary/travel/airline/">airline stocks</a>, like JetBlue (NASDAQ:<a href="https://investorplace.com/stock-quotes/jblu-stock-quote/">JBLU</a>), is also an opportunity.



Oversold at around $5.86 a share, JBLU is a buy. Going forward, I&rsquo;d initially like to see it refill its bearish gap at around $7.50.&nbsp;&nbsp;



For one, with demand taking off,&nbsp;global airlines just raised their&nbsp;<a href="https://www.thenationalnews.com/business/aviation/2024/06/03/global-airlines-raise-2024-profit-forecast-to-305bn-amid-strong-passenger-demand/">profit forecast to $30.5 billion</a>&nbsp;for the year. The industry is preparing for about five billion passengers, as noted by the International Air Transport Association. That&rsquo;s just over 11% higher than last year&rsquo;s numbers. All of which should fuel undervalued&nbsp;<a href="https://investorplace.com/industries/consumer-discretionary/travel/airline/">airline stocks</a>, like JBLU.



Two,&nbsp;<a href="https://hedgefollow.com/stocks/JBLU">top investors have been buying</a>, too. At the end of March, Carl Icahn&rsquo;s Icahn Enterprises bought 17.73 million shares. Jeffrey Talpins&rsquo; Element Capital bought 136,130 shares. Even Paul Reeder&rsquo;s Par Capital increased its stake in JBLU by nearly 50% by adding 999,500 shares.



On the&nbsp;date of publication, Ian Cooper did not hold (either&nbsp;directly or indirectly) any positions in the securities mentioned.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/?utm_source=Nasdaq&amp;utm_medium=referral">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/the-7-best-under-10-stocks-to-buy-in-july-2024/">The 7 Best Under $10 Stocks to Buy in July 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 7 Best Under $10 Stocks to Buy in July 2024

Amgen: Biotech Leader Riding High On Obesity Drug Euphoria (Downgrade)

AAPL

ABBV

ALTM

ARQT

AZNCF

GILD

GPCR

JBLU

NFLX

NONOF

PANDY

PZZA

REGN

RHHBF

RHHBY

RHHVF

SFTBY

SOUN

TCNNF

TERN

TEVA

VTRS

XPEV

ZLDPF

Screenshot 2024-06-18 at 1.15.14 AM

BRTX

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Press Releases

Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey

Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty

Investment Opportunities in Biotech Amidst Federal Rate Uncertainties (ATNM)

Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions

MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation

NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results

Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®

Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors

Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development

ARGX

ATNM

CRDL

MAIA

MRNA

NNVC

SILO

VRTX

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly and Co

Merck & Co

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Novo Nordisk

뉴스

에 대한 최신 뉴스 Novo Nordisk (NYSE:NVO) 주식

목요일, 7월 04, 2024

수요일, 6월 26, 2024

화요일, 6월 25, 2024

목요일, 6월 13, 2024

목요일, 6월 06, 2024

수요일, 5월 22, 2024

목요일, 5월 02, 2024

목요일, 4월 04, 2024

금요일, 3월 29, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌